Search results
Showing 856 to 870 of 1136 results for pain
treated in general wards in hospital and experience significant symptoms of pain and bleeding (haematuria). To explore this research...
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for IPG580Show all sections
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
session)• patient reported outcomes including dyspnoea, anxiety, delirium, pain, discomfort, breathlessness, impact on sleep• mortality•...
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)
Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.
View recommendations for MTG58Show all sections
Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula (IPG507)
Evidence-based recommendations on insertion of a collagen plug to close an abdominal wall enterocutaneous fistula. This involves inserting a collagen plug into the fistula to seal off where it joins the bowel.
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)
Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.
Brain tumours (primary) and brain metastases in over 16s (QS203)
This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.
View quality statements for QS203Show all sections
Sections for QS203
- Quality statements
- Quality statement 1: GP direct access to MRI
- Quality statement 2: Named healthcare professional
- Quality statement 3: 5-aminolevulinic acid-guided resection
- Quality statement 4: Risk of late effects of treatment
- Quality statement 5: Neurological rehabilitation
- About this quality standard
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)
Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for IPG423Show all sections
Sections for IPG423
Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. This involves inserting titanium implants to replace broken bones in the face as part of orofacial reconstruction.
View recommendations for IPG449Show all sections
Sections for IPG449
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.